Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.15. Advaxis shares last traded at $2.15, with a volume of 1,840 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Advaxis in a research report on Monday, August 22nd. They set a "sell" rating on the stock.

Advaxis Stock Performance

The stock has a market capitalization of $3.90 million, a price-to-earnings ratio of -21.50 and a beta of 2.07. The company has a 50 day simple moving average of $3.37.

Advaxis Company Profile

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

See Also

• Get a free copy of the StockNews.com research report on Advaxis (ADXS)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Will Crowdstrike Get A Boost From Increased EPS Guidance?
• 2 Semiconductor Stocks To Watch For Reversals
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.